This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Health Winners & Losers

Health care stocks were up slightly Wednesday following successful drug studies, announced stock offerings and mixed earnings.

Advanced Life Sciences Holdings (ADLS) announced that its respiratory antibiotic, Cethromycin, was shown to be effective in preventing inhalation anthrax infection in a 30-day study involving 30 primates. Shares rose 27 cents, or 7.9%, to $3.67.

Positive study results also sent Nabi Biopharmaceuticals (NABI) soaring 90 cents, or 17%, to $6.03. The company said a significant number of patients in its phase IIb study for NicVax, a vaccine to treat nicotine addiction, met the primary endpoint of eight weeks of continuous abstinence. Nabi is also set to release first-quarter financial results by end-of-day Wednesday.

Planned stock offerings also moved the market Wednesday. Immunomedics (IMMU - Get Report) announced it will sell just over 4.8 million shares of common stock to institutional investors for about $24 million, or $4.95 a share. The stock closed at $5.35 Tuesday. The offering is set to close on or around May 7. Shares were up 4 cents, or 0.8%, to $5.39.

Array BioPharma's (ARRY - Get Report) offer to sell 7 million shares for $13 a share did not have the same impact on investors. The company's stock price fell 53 cents, or 3.9%, to $13. The Array BioPharma offering is also expected to close on or around May 7.

A narrowed quarter-over-quarter loss helped make Pozen (POZN - Get Report) a winner Wednesday. The pain reduction drug developer reported a net loss of $2.1 million, or 7 cents a share for the first quarter ended March 31, compared to a net loss of $6.4 million, or 22 cents a share for the same quarter last year. The results were good enough to beat the Thomson Financial consensus of a loss of 9 cents a share. Shares hiked 80 cents, or 5.5%, to $15.30.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
NABI $10.80 0.00%
AGN $240.22 1.21%
ADLS $0.02 0.00%
CGPI $0.00 0.00%
ARRY $7.30 0.00%


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs